Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

Omaha, Nebraska 68198


This study investigates hypothesizes that the combination of dobutamine stress echocardiography with dobutamine stress echocardiography with real time perfusion myocardial contrast echocardiography and coronary computed tomography is a better modality for detecting coronary artery disease in end-stage renal disease patients than coronary angiography, and in predicting patient outcomes. Demonstrating this would lead to increased use of DSE with RTCE and coronary CT at kidney transplant centers throughout the nation, leading to improved anatomical and functional detection of CAD without the need for further invasive procedures.

Study summary:

Primary: To examine the ability of dobutamine stress dobutamine stress echocardiography with real time perfusion (DSE with RTCE) and coronary computed tomographic angiography (cCTA) to detect anatomically significant coronary artery disease (CAD) as defined by quantitative coronary angiography in end-stage renal disease (ESRD) patients Secondary: To identify which of these tests is most predictive of patient outcomes. This will be a pilot study enrolling 75 participants. This is based off obtaining 80% power and a 90% rectangular confidence region for sensitivity and specificity using one-sided confidence limits, this corresponds to two 95% univariate confidence intervals (one for sensitivity and one for specificity). With 73 patients screened in total there will be 80% power to form a 90% rectangular confidence region around 90% sensitivity and 90% specificity, excluding sensitivities less than 69% and specificities less than 73%. We believe the sensitivities and specificities of both DSE with RTCE and cCTA will be within these confidence regions.


Inclusion Criteria: 1. Diabetes mellitus 2. Patients undergoing kidney transplant evaluation. 3. Currently on hemodialysis 4. Adults 19-65 years of age 5. Written informed consent from a participant who is deemed medically competent by principal investigator, secondary investigators, or participating personnel as written in II.26 (b) 6. Male or female Exclusion Criteria: 1. Previous history of percutaneous coronary intervention 2. Coronary artery bypass surgery 3. Prior myocardial infarction or AMI (troponin greater than 1.0) within 48 hours of the test 4. Atrial or ventricular arrhythmias that cannot be controlled to heart rates <65 beats per minute 5. Known allergy to iodinated contrast 6. Decompensated Congestive Heart failure 7. Acute respiratory failure as manifested by signs and symptoms of carbon dioxide retention or hypoxemia 8. Pregnant (based on history/information obtained from the patient) 9. Possibility that potential subject may be pregnant (based on history/information obtained from the patient)



Primary Contact:

Principal Investigator
Thomas R Porter, MD
UNMC Department of Cardiology

Thomas R Porter, MD
Phone: 402-559-7977
Email: trporter@unmc.edu

Backup Contact:

Email: gwardyn@unmc.edu
Gina G Wardyn, MD
Phone: 402-690-1685

Location Contact:

Omaha, Nebraska 68198
United States

There is no listed contact information for this specific location.

Site Status: N/A

Data Source: ClinicalTrials.gov

Date Processed: January 17, 2018

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.